Globus Medical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Globus Medical reported 3rd quarter 2026 revenue of $763.7 million, down 0.7% as reported and 0.5% on a constant currency basis.
- Base business revenue excluding Nevro was $690 million, growing 3% as reported, while Nevro revenue was $73.7 million, declining 25.7% year over year.
- U.S. Spine grew 2% over the prior year quarter; Enabling Technologies revenue was $34.9 million, growing 24%; and trauma grew 19%.
- Non-GAAP fully diluted earnings per share were $1.23, up 4.4% year over year, and adjusted gross profit margin was 69.5%, up 140 basis points from the prior year quarter.
- Free cash flow was a record $225 million despite a 13% increase in capital expenditures, and the company repurchased $142.9 million, or 1.9 million shares, during the quarter.
- Nevro adjusted EBITDA margins expanded 370 basis points, while total company adjusted EBITDA margin was 34.3%, compared with 32.8% in the prior year quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to Globus Medical's third quarter 2026 earnings call. At this time, all lines will be on mute, and a Q&A session will be held after the prepared remarks. I will now turn the call over to Shagun Singh, Senior Vice President of Strategy and Investor Relations. Ms. Singh, please go ahead.
Thank you for being with us today. Joining today's call from Globus Medical will be Keith Pfeil, President and Chief Executive Officer, and Kyle Kline, Chief Financial Officer. This review is being made available via webcast, accessible through the Investor Relations section of the Globus Medical website at www.globusmedical.com. As a reminder, our discussion may include forward-looking statements, and such statements are subject to risks and uncertainties that could cause actual and anticipated results to differ materially. Please refer to the cautionary language in the earnings release and in the company's filings with the Securities and Exchange Commission for additional information. Except as may be required by applicable law, we do not undertake to update any forward-looking statements. Additionally, we will be discussing certain non-GAAP financial measures on this conference call. We believe these non-GAAP financial measures provide additional information pertinent to our business performance.
They should not, however, be considered replacements for or should be read together with the most directly comparable GAAP financial measures. Additional information regarding these non-GAAP financial measures, as well as reconciliations for such non-GAAP measures, are included in the earnings release and are available on the Investor Relations section of the Globus Medical website. With that, I will now turn the call over to Keith Pfeil, our President and Chief Executive Officer.
Thanks, Shagun, and good afternoon, everyone. Before I discuss the quarter, I'd like to formally welcome Shagun Singh to Globus as our new Senior Vice President of Strategy and Investor Relations. Shagun brings more than 20 years of healthcare investment research experience with deep expertise in medical technology and the investment landscape. She will lead our investor relations function as we expand engagement with our shareholders. As our business has grown in size and complexity, we've separated investor relations from corporate development so that each has dedicated leadership. Brian Kearns, who has led both functions for the past 12 years, will continue as Senior Vice President of Corporate Development. I want to thank Brian for the work he's done building relationships with many of you on this call. With that, let's turn to our third quarter results and the longer-term outlook.
Our third quarter results totaled $763.7 million, declining 0.7% on an as-reported basis and declining 0.5% on a constant currency basis, reflecting the continued impacts of our rightsizing of Nevro, the timing of delayed new product launches within U.S. Spine, and lower contributions from competitive recruiting. Base business revenue, excluding Nevro, was $690 million, growing 3% as reported, while Nevro was $73.7 million, declining 25.7% compared to the prior year quarter. Non-GAAP EPS was $1.23, growing 4% over the prior year quarter, while free cash flow was a record $225 million, despite a 13% increase in capital expenditures. Lastly, we deployed $143 million to repurchase 1.9 million shares during the quarter, maintaining our commitment to share buybacks as part of our capital allocation strategy.
Our U.S. Spine business grew 2% over the prior year quarter, coming off of a tough comp with a slowdown attributed to timing delays around new product launches and lower contributions from competitive recruiting. We have experienced timing delays with new product introductions and lingering production issues. However, actions taken over the past few months are beginning to improve this globally, which will favorably impact our growth as we enter 2027. Growth from new products has been lower than expected due to the timing of key launches. We expect these launches to drive meaningful growth as we enter 2027. On the competitive recruiting front, we need to continually increase the pace of our territory expansions and are taking steps to onboard competitive reps, as well as hiring, training, and developing new territories.
Looking ahead over the longer term, we remain confident in our ability to grow our U.S. Spine business above market, centered around meaningful new product launches, pull-through growth from capital attachments, and competitive recruiting. Organic innovation still matters and becomes more powerful when you pair that with a strong core spine business, differentiated enabling technologies, and the ability to scale. We possess those core traits and will use them as an advantage as we attack the market and specifically target growth opportunities based on potential market disruptions and dislocations. Now, turning attention to key spine product launches, our SCRIPT line of patient-specific implants and rods represents a major launch for Globus into the fast-growing patient-specific implant category. SCRIPT is comprised of seven new 3D-printed interbody cages and new patient-specific rods.
Unlike competitive offerings in this space, SCRIPT will expand expandable and interfixated cage options, in addition to static offerings across ALIF, XLIF, and TLIF categories. Each personalized implant is designed virtually using the new Globus SCRIPT Studio software application, allowing surgeons to customize each implant to patient specifications. Combining SCRIPT with our full line of implant offerings and market-leading Excelsius technologies positions us as a differentiator in this space, given our full complement of product offerings. Our new XLIF Prone Solution showcases our continued ability to innovate in a category we pioneered, and we will continue our technology leadership in this space as it features a newly enhanced patient positioner and the MaXcess Air two-blade retractor. The overall solution brings together patient positioning, lateral access, and enabling technologies in a manner that is designed to support a connected workflow for prone lateral procedures.
These new solutions combine adaptable patient positioning with stable, controlled lateral access to establish a reproducible workflow for prone lateral procedures. The XLIF Prone Patient Positioner allows adjustments in both the sagittal and coronal planes, while the MaXcess Air Retractor provides a lightweight, rigid platform designed to support soft tissue management and stable access to the disc space. The SCRIPT line of implants and rods are currently available, while the XLIF Prone Solution and two-blade retractor will be available later this quarter. Additionally, we are in the final stages of introducing a revolutionary product suite called eIQ, which includes a next-generation pedicle fixation product comprised of implants, instruments, AI-based software planning and execution tools, an intraoperative rod bending machine, and integrated neuromonitoring, all working seamlessly with our ExcelsiusGPS robot, ExcelsiusHub navigation, and Excelsius3D imaging systems.
We are excited about these products and expect them to be meaningful contributors to revenue in 2027 and beyond. Our enabling technologies business delivered $34.9 million to the third quarter, growing 24%, driven by increased upfront sales of robots, as well as a continued increase in service revenue. In addition to the increase in upfront revenue, our overall ExcelsiusGPS and ExcelsiusHub units deployed, whether sold, leased, or rented, grew 73% versus the prior year quarter. Looking at the comparable year-to-date figure, our overall ExcelsiusGPS and ExcelsiusHub units deployed are 65% higher versus the prior year to date, demonstrating early results of our approach to increased flexibility in how capital is acquired. During the third quarter, the FDA notified us of the closure of the July 2024 ExcelsiusGPS warning letter as a result of the corrective action steps taken.
As a reminder, the warning letter was focused on administrative tracking of complaint handling and was not an issue of patient safety. Appropriate notifications were shared with both our sales force and customers regarding the letter's closure. We remain positive on the benefits of our ExcelsiusGPS technology, with over 145,000 robotic cases performed to date, and see this and navigation with our ExcelsiusHub as key drivers to implant revenue growth in 2027 and beyond. Our Q3 Trauma business grew 19% as compared to the prior year quarter. Reflecting on our Trauma performance the past few years, the business has remained on a steady growth trajectory. We see surgeons, health systems, reps, and competition beginning to look at Globus Trauma differently. In the past, Globus was known as a spine company dabbling in the Trauma space.
That narrative has shifted, where we are now being viewed as a company that is committed to the space and investing in it. Our growth strategy remains focused on converting surgeon teams within level 1 and level 2 trauma centers such that we achieve set utilization, driving long-term profitable growth. As we look ahead to 2027 and beyond, we expect our Trauma business to contribute incrementally higher each year to our consolidated growth going forward. Q3 Nevro revenue totaled $73.7 million, declining 26% as compared to the prior year quarter, given the earlier declines in U.S. trial volumes. Despite the revenue declines, Nevro adjusted EBITDA margins expanded 370 basis points, driven by gross margin expansion and a more disciplined approach to OPEX spending. As we work to recoup lost revenue, we are fully confident that we've right-sized the business, which can now operate in a sustainable manner.
We substantially completed the rehiring of sales headcount lost earlier in the year and are starting to see increased output from new associates trained. As we look ahead, we remain focused on stabilizing and getting this business back to a path of growth. The revenue recovery will be driven by increasing the execution of our sales force and growing it through competitive recruiting. In addition, we seek to bring new products to market, and I am excited to share that we will be introducing a new IPG in 2027 named HFX Elite, which is the first innovation to the market since the acquisition of Nevro. HFX Elite will introduce bolus therapy and expanded MRI labeling, allowing more patients access to MRI.
HFX Elite is slated for a first-half 2027 commercial launch, which we see as a catalyst to drive revenue growth in the new year, as we remain committed to the pain market. While Nevro introduced a new continuum of care to Globus with the introduction of pain to our spine franchise, I want to remind everyone that an entry point into pain and SCS were not the only reasons to acquire Nevro. For an acquisition price of $250 million, we have added a technology tuck-in to our portfolio and continue to see uses of the Nevro technology beyond what it is today, which we see as drivers to expand the technologies and product development into new areas, including cranial, next-gen spinal implants, as well as peripheral nerve stimulation.
Transitioning this business to a sustainable model of profitability was critical as we investigate the technologies for alternative uses while still working to develop and launch new and exciting products within the core pain franchise. Now that I have covered the quarter pertaining to our business performance, I would like to step back and spend a few minutes on who we are, where we are going, and why we are making those decisions along the way, as it will help evaluate us over the next several years. First, our strategy and focus are to develop technologies and procedural solutions that span the continuum of care in the categories in which we operate. We want to innovate, disrupt, and develop a moat that advances patient care while driving operational excellence.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
